Corpus ID: 13572617

Efalizumab. Anti-CD11a monoclonal antibody--Genentech/Xoma, HU 1124, hu1124, xanelim.

@article{2002EfalizumabAM,
  title={Efalizumab. Anti-CD11a monoclonal antibody--Genentech/Xoma, HU 1124, hu1124, xanelim.},
  author={},
  journal={Drugs in R\&D},
  year={2002},
  volume={3 1},
  pages={
          40-3
        }
}
  • Published 2002
  • Medicine
  • Drugs in R&D
The Role of Methotrexate in Psoriatic Therapy in the Age of Biologic and Biosimilar Medication: Therapeutic Benefits versus Toxicology Emergencies
Used in the psoriasis therapy for over 30 years, methotrexate belongs to the non‐bio‐ logical medication class. Its continued use must be studied in the context of the modern unprecedented powerfulExpand
Biosimilars in psoriasis: What can we expect?
  • M. Radtke, M. Augustin
  • Medicine
  • Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2014
TLDR
From a medical and health care perspective, specific evidence‐based regulatory conditions need to be created and fulfilled before biosimilars enter the market, and adequate, unequivocal proof of their bioequivalence, quality, and related patient safety should have priority over any ostensible economic benefits. Expand
Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences
TLDR
The mainstay armamentarium to treat psoriasis systemically includes methotrexate, ciclosporin and oral retinoids, all with significant potential for toxicity and the need for close laboratory supervision but the advantages of these biological agents are less toxic systemic side‐effect profiles that will improve the quality of life in psoriatic patients. Expand